7464-11-1

Usage

Uses

Used in Pharmaceutical Industry:
3,5-dichloro-8-methyl-9-thia-2,4,7-triazabicyclo[4.3.0]nona-2,4,7,10-tetraene is used as a pharmaceutical compound for its potential medicinal properties. Its unique structure may contribute to the development of new drugs, particularly in the areas of therapeutic agents and drug delivery systems.
Used in Agrochemical Industry:
In the agrochemical sector, 3,5-dichloro-8-methyl-9-thia-2,4,7-triazabicyclo[4.3.0]nona-2,4,7,10-tetraene is used as a chemical intermediate for the synthesis of agrochemicals. Its reactivity and structural features can be leveraged to create new pesticides or herbicides, enhancing crop protection and yield.
Used in Materials Science:
3,5-dichloro-8-methyl-9-thia-2,4,7-triazabicyclo[4.3.0]nona-2,4,7,10-tetraene is utilized in materials science for the development of novel materials with specific properties. Its potential use in creating advanced polymers, coatings, or other materials with unique characteristics can contribute to various technological and industrial applications.

InChI:InChI=1/C6H3Cl2N3S/c1-2-9-3-4(7)10-6(8)11-5(3)12-2/h1H3

Upstream product

• 5021-52-3 2-methyl-4H-thiazolo[5,4-d]pyrimidine-5,7-dione 
• 31785-16-7 5-amino-2-methyl-thiazole-4-carbonitrile 
• 503-38-8 trichloromethyl chloroformate 
• 5021-52-3 2-Methyl-thiazolo<5,4-d>pyrimidin-5,7-diol 
• 1093074-91-9 2-methyl-5-ureido-thiazole-4-carboxylic acid ethyl ester 
• 90877-70-6 ethyl 2-acetamido-2-cyanoacetate 
• 31785-05-4 5-amino-2-methyl-1,3-thiazole-4-carboxylic acid ethyl ester 

Downstream Products

• 1093075-03-6 5-chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine-2-carbaldehyde 
• 1093075-04-7 5-chloro-7-morpholin-4-yl-2-styryl-thiazolo[5,4-d]pyrimidine 
• 1093075-02-5 2-(5-chloro-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidin-2-yl)-1-phenyl-ethanol 

Relevant academic research and scientific papers

Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1 and A2A adenosine receptor antagonists/inverse agonists

In this study a new set of thiazolo[5,4-d]pyrimidine derivatives was synthesized. These derivatives bear different substituents at positions 2 and 5 of the thiazolopyrimidine core while maintaining a free amino group at position-7. The new compounds were tested for their affinity and potency at human (h) A1, A2A, A2B and A3 adenosine receptors expressed in CHO cells. The results reveal that the higher affinity of these new set of thiazolopyrimidines is toward the hA1 and hA2A adenosine receptors subtypes and is tuned by the substitution pattern at both the 2 and 5 positions of the thiazolopyrimidine nucleus. Functional studies evidenced that the compounds behaved as dual A1/A2A antagonists/inverse agonists. Compound 3, bearing a 5-((2-methoxyphenyl) methylamino) group and a phenyl moiety at position 2, displayed the highest affinity (hA1 Ki = 10.2 nM; hA2A Ki = 4.72 nM) and behaved as a potent A1/A2A antagonist/inverse agonist (hA1 IC50 = 13.4 nM; hA2A IC50 = 5.34 nM).

HETEROCYCLIC JAK KINASE INHIBITORS

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer

THIAZOLIOPYRIMIDINES AND THEIR USE AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3 KINASE

Thiazolopyrimidines of formula (I): wherein W represents a thiazole ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is a ring system; m is 0, 1 or 2; Rsup